Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase. clinical trial.

被引：0
|
作者：
Zhang, Yan-Feng
Li, Xiao-Bing
Hong, Yong-Gui
Li, Xiao-Ming
Liang, Wei-Min
Zheng, Zhi-Xin
Yang, Guang-Yi
Wen, Yan-Yan
Cao, Heng
Wu, Wei-Long
Su, Wen-Zhong
机构：
[1] Anyang Tumor Hosp, Anyang, Peoples R China
[2] Anyang Tumour Hosp, Anyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial.
    Zhao, Heng
    Geng, Jiayi
    Zhou, Lixin
    Chang, Geyun
    Yan, Xiang
    Yang, Fan
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS506 - TPS506
  • [32] Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS)
    Jiang, Youhua
    Qiu, Guoqin
    Li, Jianqiang
    Wang, Jiangfeng
    Wang, Changchun
    Wu, Jie
    Cheng, Lei
    Zheng, Yuanda
    Ruan, Rongwei
    Song, Ge
    Ye, Xuemei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Camrelizumab combined with albumin paclitaxel and cisplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC).
    Lv, Huilai
    Tian, Yang
    Huang, Chao
    Li, Zhenhua
    Tian, Ziqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial
    Hong, G.
    Meng, X.
    Yang, X.
    Zhang, Z. Y.
    Xia, J.
    Chen, Y-F.
    Wu, T.
    Shan, Z.
    Fan, Q.
    Wang, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S861 - S861
  • [35] Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma
    Fan, Yun
    Jiang, Youhua
    Zhou, Xinming
    Chen, Qixun
    Huang, Zhiyu
    Xu, Yanjun
    Gong, Lei
    Yu, Haifeng
    Yang, Haiyan
    Liu, Jinshi
    Lei, Tao
    Zhao, Qiang
    Mao, Weimin
    ONCOTARGET, 2016, 7 (31) : 50624 - 50634
  • [36] The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.
    Huang, Naisi
    Sun, Guohua
    Wang, Yulong
    Chen, Jiaying
    Guan, Qing
    Lu, Zhongwu
    Xiang, Jun
    Wei, Wenjun
    Ma, Ben
    Ji, Qinghai
    Wang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial
    Wang, Jie
    Li, Bin
    Zhang, Yawei
    Luo, Xiaoyang
    Zhang, Yiliang
    Li, Hang
    Pan, Yunjian
    Shao, Longlong
    Zheng, Shanbo
    Yuan, Chongze
    Li, Yuan
    Zheng, Qiang
    Sun, Si
    Zhao, Weixin
    Sun, Yihua
    INTERNATIONAL JOURNAL OF CANCER, 2025, 156 (07) : 1429 - 1438
  • [38] Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
    Bai, Chunmei
    Wang, Chenyu
    Jia, Ning
    Chen, Xingming
    Zhu, Xiaoli
    Sun, Shuai
    Shi, Xiaohua
    Chen, Yu
    Luo, Yaping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)
    Yang, Yingnan
    Zhang, Jinfeng
    Meng, Hongxue
    Ling, Xiaodong
    Wang, Xiaoyuan
    Xin, Yanzhong
    Jiang, Hao
    Zhang, Luquan
    Fang, Chengyuan
    Liang, Hao
    Ma, Jianqun
    Zhu, Jinhong
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (03) : 1430 - 1440
  • [40] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
    Liu, Jun
    Yang, Yang
    Liu, Zhichao
    Fu, Xiaolong
    Cai, Xiaoyue
    Li, Hongxuan
    Zhu, Li
    Shen, Yan
    Zhang, Hong
    Sun, Yifeng
    Chen, Hezhong
    Yu, Bentong
    Zhang, Renquan
    Shao, Jinchen
    Zhang, Ming
    Li, Zhigang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
12345